Programmed death ligand 1 (PD-L1) protein expression in tumor tissue, and tumor mutational burden (TMB), defined as the number of acquired amino acid sequence-changing mutations2, is currently used to predict the efficacy of immunotherapy in NSCLC3. This evidence concerns the gene CD274 and neoplasm.